AA (Inflammatory) Amyloidosis Questions & Answers

1. Pinney JH, Lachmann HJ. Systemic AA Amyloidosis. Subcell Biochem. 2012. 65:541-64. [QxMD MEDLINE Link].

2. Papa R, Lachmann HJ. Secondary, AA, Amyloidosis. Rheum Dis Clin North Am. 2018 Nov. 44 (4):585-603. [QxMD MEDLINE Link]. [Full Text].

3. Ogawa S, Murakami T, Inoshima Y, Ishiguro N. Effect of heating on the stability of amyloid A (AA) fibrils and the intra- and cross-species transmission of AA amyloidosis. Amyloid. 2015 Nov 20. 1-8. [QxMD MEDLINE Link].

4. Quock TP, Yan T, Chang E, Guthrie S, Broder MS. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22. 2 (10):1046-1053. [QxMD MEDLINE Link].

5. Perfetto F, Moggi-Pignone A, Livi R, Tempestini A, Bergesio F, Matucci-Cerinic M. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010 Jul. 6(7):417-29. [QxMD MEDLINE Link].

6. Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol. 2015 Nov-Dec. 33 (6 Suppl 94):46-53. [QxMD MEDLINE Link].

7. Westermark GT, Fändrich M, Westermark P. AA amyloidosis: pathogenesis and targeted therapy. Annu Rev Pathol. 2015. 10:321-44. [QxMD MEDLINE Link].

8. Obici L, Raimondi S, Lavatelli F, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum. 2009 Oct 15. 61(10):1435-40. [QxMD MEDLINE Link].

9. Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid. 1999 Mar. 6(1):67-70. [QxMD MEDLINE Link].

10. van der Hilst JC, Yamada T, Op den Camp HJ, van der Meer JW, Drenth JP, Simon A. Increased susceptibility of serum amyloid A 1.1 to degradation by MMP-1: potential explanation for higher risk of type AA amyloidosis. Rheumatology (Oxford). 2008 Nov. 47(11):1651-4. [QxMD MEDLINE Link].

11. Brunger AF, Nienhuis HLA, Bijzet J, Hazenberg BPC. Causes of AA amyloidosis: a systematic review. Amyloid. 2020 Mar. 27 (1):1-12. [QxMD MEDLINE Link].

12. Bunker D, Gorevic P. AA amyloidosis: Mount Sinai experience, 1997-2012. Mt Sinai J Med. 2012 Nov-Dec. 79 (6):749-56. [QxMD MEDLINE Link].

13. Siman-Tov R, Shalabi R, Shlomai A, Goldberg E, Essa W, Shusterman E, et al. Elevated Serum Amyloid A Levels Contribute to Increased Platelet Adhesion in COVID-19 Patients. Int J Mol Sci. 2022 Nov 17. 23 (22):[QxMD MEDLINE Link].

14. Jasim SA, Mahdi RS, Bokov DO, Najm MAA, Sobirova GN, Bafoyeva ZO, et al. The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: An update. J Med Virol. 2022 Nov. 94 (11):5128-5148. [QxMD MEDLINE Link].

15. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7. 356(23):2361-71. [QxMD MEDLINE Link].

16. Silva L, Sampaio L, Terroso G, Almeida G, Lucas R, Rios E, et al. Amyloidosis secondary to rheumatic diseases - 16 cases. Acta Reumatol Port. 2010 Oct-Dec. 35(5):518-23. [QxMD MEDLINE Link].

17. Kang SJ, Yi JH, Hong HS, Jang SH, Park MH, Kim HJ, et al. Secondary amyloidosis associated with multiple sclerosis. J Clin Neurol. 2009 Sep. 5 (3):146-8. [QxMD MEDLINE Link].

18. Wester AL, Vatn MH, Fausa O. Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis. 2001 Nov. 7(4):295-300. [QxMD MEDLINE Link].

19. Lejmi H, Jen KY, Olson JL, James SH, Sam R. Characteristics of AA amyloidosis patients in San Francisco. Nephrology (Carlton). 2016 Apr. 21 (4):308-13. [QxMD MEDLINE Link].

20. Bharati J, Lahoud OB, Jhaveri KD, Izzedine H. AA Amyloidosis associated with cancers. Nephrol Dial Transplant. 2022 Jul 22. [QxMD MEDLINE Link].

21. Bernabei L, Waxman A, Caponetti G, Fajgenbaum DC, Weiss BM. AA amyloidosis associated with Castleman disease: A case report and review of the literature. Medicine (Baltimore). 2020 Feb. 99 (6):e18978. [QxMD MEDLINE Link]. [Full Text].

22. Beloncle F, Sayegh J, Eymerit-Morin C, Duveau A, Augusto JF. AA amyloidosis as a complication of primary lymphedema. Amyloid. 2013 Aug 21. [QxMD MEDLINE Link].

23. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7. 356 (23):2361-71. [QxMD MEDLINE Link].

24. Lee H, Han KH, Jung YH, Kang HG, Moon KC, Ha IS, et al. A case of systemic amyloidosis associated with cyclic neutropenia. Pediatr Nephrol. 2011 Apr. 26(4):625-9. [QxMD MEDLINE Link].

25. Delplanque M, Galicier L, Oziol E, Ducharme-Bénard S, Oksenhendler E, Buob D, et al. AA amyloidosis secondary to primary immune deficiency: about 40 cases including 2 new French cases and a systematic literature review. J Allergy Clin Immunol Pract. 2020 Sep 29. [QxMD MEDLINE Link].

26. Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol. 1994 Aug. 8(3):627-34. [QxMD MEDLINE Link].

27. Kuroda T, Tanabe N, Nozawa Y, Sato H, Nakatsue T, Kobayashi D, et al. Effects of Biologic Agents in Patients with Rheumatoid Arthritis and Amyloidosis Treated with Hemodialysis. Intern Med. 2016. 55 (19):2777-2783. [QxMD MEDLINE Link]. [Full Text].

28. Yildirim Cetin G, Ganiyusufoglu E, Solmaz D, Cagatay Y, Yılmaz Oner S, Erer B, et al. The rate and significance of type 1/type 2 serum amyloid A protein gene polymorphisms in patients with ankylosing spondylitis and amyloidosis. Amyloid. 2015. 22 (3):207-8. [QxMD MEDLINE Link].

29. Booth DR, Booth SE, Gillmore JD, et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998 Dec. 5(4):262-5. [QxMD MEDLINE Link].

30. Joss N, McLaughlin K, Simpson K, et al. Presentation, survival and prognostic markers in AA amyloidosis. QJM. 2000 Aug. 93(8):535-42. [QxMD MEDLINE Link].

31. Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007 Jun 7. 356(23):2361-71. [QxMD MEDLINE Link].

32. Myllykangas-Luosujärvi R, Aho K, Kautiainen H, Hakala M. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland. Rheumatology (Oxford). 1999 Jun. 38(6):499-503. [QxMD MEDLINE Link].

33. Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001 Jul 7. 358(9275):24-9. [QxMD MEDLINE Link].

34. Immonen K, Finne P, Hakala M, Kautiainen H, Pettersson T, Grönhagen-Riska C. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. J Rheumatol. 2008 Jul. 35(7):1334-8. [QxMD MEDLINE Link].

35. Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003 May-Jun. 21(3):343-6. [QxMD MEDLINE Link].

36. Papathanasiou M, Carpinteiro A, Rischpler C, Hagenacker T, Rassaf T, Luedike P. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. Int J Cardiol Heart Vasc. 2020 Jun. 28:100519. [QxMD MEDLINE Link]. [Full Text].

37. Uda H, Yokota A, Kobayashi K, Miyake T, Fushimi H, Maeda A, et al. Two distinct clinical courses of renal involvement in rheumatoid patients with AA amyloidosis. J Rheumatol. 2006 Aug. 33(8):1482-7. [QxMD MEDLINE Link].

38. Enríquez R, Sirvent AE, Padilla S, Noguera-Pons R, Andrada E, Ardoy F, et al. Nephrotic syndrome and AA amyloidosis revealing adult-onset cryopyrin-associated periodic syndrome. Ren Fail. 2013. 35(5):738-41. [QxMD MEDLINE Link].

39. Sattianayagam PT, Gillmore JD, Pinney JH, Gibbs SD, Wechalekar AD, Gilbertson JA, et al. Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci. 2013 Jun. 58(6):1689-97. [QxMD MEDLINE Link].

40. Yildiz L, Kefeli M, Kose B, Baris S. Amyloid goiter: two cases and a review of the literature. Ann Saudi Med. 2009 Mar-Apr. 29 (2):138-41. [QxMD MEDLINE Link].

41. Wens R, Goffin Y, Pepys MB, Kutnowski M, Van Beers D, Decoodt P, et al. Left atrial myxoma associated with systemic AA amyloidosis. Arch Intern Med. 1989 Feb. 149 (2):453-4. [QxMD MEDLINE Link].

42. Balint GP, Balint PV. Felty's syndrome. Best Pract Res Clin Rheumatol. 2004 Oct. 18 (5):631-45. [QxMD MEDLINE Link].

43. Westermark P, Stenkvist B. A new method for the diagnosis of systemic amyloidosis. Arch Intern Med. 1973 Oct. 132 (4):522-3. [QxMD MEDLINE Link].

44. Picken MM. Amyloidosis-where are we now and where are we heading?. Arch Pathol Lab Med. 2010 Apr. 134(4):545-51. [QxMD MEDLINE Link].

45. Mercan R, Bıtık B, Tezcan ME, Kaya A, Tufan A, Ozturk MA, et al. Minimally invasive minor salivary gland biopsy for the diagnosis of amyloidosis in a rheumatology clinic. ISRN Rheumatol. 2014. 2014:354648. [QxMD MEDLINE Link]. [Full Text].

46. Freudenthaler S, Hegenbart U, Schönland S, Behrens HM, Krüger S, Röcken C. Amyloid in biopsies of the gastrointestinal tract-a retrospective observational study on 542 patients. Virchows Arch. 2016 May. 468 (5):569-77. [QxMD MEDLINE Link]. [Full Text].

47. Wall JS, Williams A, Richey T, Stuckey A, Huang Y, Wooliver C, et al. A binding-site barrier affects imaging efficiency of high affinity amyloid-reactive peptide radiotracers in vivo. PLoS One. 2013. 8 (6):e66181. [QxMD MEDLINE Link].

48. Livneh A, Zemer D, Langevitz P, et al. Colchicine treatment of AA amyloidosis of familial Mediterranean fever. An analysis of factors affecting outcome. Arthritis Rheum. 1994 Dec. 37(12):1804-11. [QxMD MEDLINE Link].

49. Solak Y, Siriopol D, Yildiz A, Yilmaz MI, Ortiz A, Covic A, et al. Colchicine in Renal Medicine: New Virtues of an Ancient Friend. Blood Purif. 2017. 43 (1-3):125-135. [QxMD MEDLINE Link]. [Full Text].

50. Ahlmen M, Ahlmen J, Svalander C, et al. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol. 1987 Mar. 6(1):27-38. [QxMD MEDLINE Link].

51. Fernández-Nebro A, Tomero E, Ortiz-Santamaría V, Castro MC, Olivé A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med. 2005 May. 118(5):552-6. [QxMD MEDLINE Link].

52. Leslie KS, Lachmann HJ, Bruning E, McGrath JA, Bybee A, Gallimore JR, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol. 2006 Dec. 142(12):1591-7. [QxMD MEDLINE Link].

53. Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017 May 30. 12 (1):105. [QxMD MEDLINE Link]. [Full Text].

54. Kovács A, Cserenyecz A, Baksay B, Kemény É, Szekanecz Z. Successful Treatment of Rheumatoid Arthritis-Associated Renal AA Amyloidosis with Tocilizumab. Isr Med Assoc J. 2020 Jul. 7 (22):389-391. [QxMD MEDLINE Link].

55. Esatoglu SN, Hatemi G, Ugurlu S, Gokturk A, Tascilar K, Ozdogan H. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine (Baltimore). 2017 Aug. 96 (34):e7859. [QxMD MEDLINE Link]. [Full Text].

56. Green H, Lichtenberg S, Rahamimov R, Livneh A, Chagnac A, Mor E, et al. Familial Mediterranean Fever Is Associated With Increased Mortality After Kidney Transplantation-A 19 Years' Single Center Experience. Transplantation. 2017 Oct. 101 (10):2621-2626. [QxMD MEDLINE Link].

57. Altindal M, Turkmen E, Yildirim T, Yilmaz R, Aki FT, Arici M, et al. Kidney transplantation for end-stage renal disease secondary to familial Mediterranean fever. Clin Transplant. 2016 Jul. 30 (7):787-90. [QxMD MEDLINE Link].

58. Tatar E, Karatas M, Aykas A, Okut G, Bozkaya G, Uslu A. Infections After Renal Transplant in Recipients With Familial Mediterranean Fever: A Life-Threatening Issue. Exp Clin Transplant. 2017 Feb. 15 (Suppl 1):240-243. [QxMD MEDLINE Link]. [Full Text].

59. Kofman T, Grimbert P, Poitrine FC, Zuber J, Garrigue V, Mousson C, et al. Renal Transplantation in Patients With AA Amyloidosis Nephropathy: Results From a French Multicenter Study. Am J Transplant. 2011 Jun 30. [QxMD MEDLINE Link].

60. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011 Apr. 6 (4):913-21. [QxMD MEDLINE Link].

Jefferson R Roberts, MD Chief of Rheumatology Service, Tripler Army Medical Center; Assistant Clinical Professor of Medicine, Uniformed Services University of the Health Sciences

Jefferson R Roberts, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, Society for Simulation in Healthcare

Disclosure: Nothing to disclose.

Victoria M F Mank, MD Resident Physician, Department of Internal Medicine, Tripler Army Medical Center

Victoria M F Mank, MD is a member of the following medical societies: American College of Physicians

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Elliot Goldberg, MD Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Lewis Katz School of Medicine at Temple University

Elliot Goldberg, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology

Disclosure: Nothing to disclose.

Herbert S Diamond, MD Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Herbert S Diamond, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians, American College of Rheumatology, American Medical Association, Phi Beta Kappa

Disclosure: Nothing to disclose.

Robert E Wolf, MD, PhD Professor Emeritus, Department of Medicine, Louisiana State University School of Medicine in Shreveport; Chief, Rheumatology Section, Medical Service, Overton Brooks Veterans Affairs Medical Center

Robert E Wolf, MD, PhD is a member of the following medical societies: American College of Rheumatology, Arthritis Foundation, Society for Leukocyte Biology

Disclosure: Nothing to disclose.

Joel N Buxbaum, MD Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute

Joel N Buxbaum, MD is a member of the following medical societies: American Association for the Advancement of Science, American Society for Clinical Investigation, American Society of Human Genetics, Association of American Physicians, Association of Black Cardiologists, Henry Kunkel Society

Disclosure: Received consulting fee from Foldrx pharmaceuticals for consulting; Received consulting fee from Isis pharmaceuticals for consulting; Received consulting fee from alnylam pharmaceutical for consulting; Received consulting fee from Pfizer Pharmaceuticals for consulting.

Eisha Mubashir, MD Fellow in Rheumatology, Department of Medicine, Center of Excellence for Arthritis and Rheumatology, Louisiana State University School of Medicine in Shreveport

Disclosure: Nothing to disclose.

Richa Dhawan, MD, CCD Associate Professor, Director of Osteoporosis Clinic, Center of Excellence for Arthritis and Rheumatology, Louisiana State University Health Science Center at Shreveport

Richa Dhawan, MD, CCD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American College of Rheumatology, American Association of Physicians of Indian Origin

Disclosure: Nothing to disclose.

Mohammed Mubashir Ahmed, MD Associate Professor, Department of Medicine, Division of Rheumatology, University of Toledo College of Medicine

Mohammed Mubashir Ahmed, MD is a member of the following medical societies: American College of Physicians, American College of Rheumatology, American Federation for Medical Research

Disclosure: Nothing to disclose.

Ratinder J Kaur, MD Fellow, Department of Rheumatology, Louisiana State University School of Medicine in Shreveport

Disclosure: Nothing to disclose.

• Print this section
• Print the entire contents of
• Print the entire contents of article